Andrew Maleki has more than a decade of biotech experience in corporate strategy, business development and operations. At Lassen Therapeutics and Jazz Pharmaceuticals, Maleki held leadership roles in corporate development, program leadership, collaborations, licensing and acquisitions.
Charles Williams has 20 years of biopharmaceutical experience in strategy, operations, finance and corporate development. Williams headed corporate development at Jazz Pharmaceuticals plc and held corporate development and finance roles at MAP Pharmaceuticals and CV Therapeutics.
Mr. Chai is a venture partner at SR One, advising portfolio companies on investor engagement and financing strategy and execution. Mr. Chai has over 20 years of executive management and investment banking experience and served as CFO of Principia Biopharma.
Dr. Daniel Chao is a retina specialist and physician scientist with over 15 years in ophthalmic research and drug development. At ADARx Pharmaceuticals and Johnson and Johnson, Dr. Chao led ophthalmology programs from discovery through late-stage development.
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to repair and restore tissue function, focused in ophthalmology.
